Valneva Shares Under Pressure Ahead of Quarterly Results, Down 47% in 3 Months

A Busy Financial Calendar Following Dilution

Valneva is set to publish its first-quarter 2026 results on Thursday, May 7th, followed by a second financial communication on May 13th. At the end of April, the biotech completed a private placement of €84 million, with €37 million received at closing and up to €47 million contingent on the exercise of subscription warrants. This operation weighed on the stock price, which broke its support at €2.32 on Monday. Beyond the quarterly release, the schedule includes participation in the Bernstein European Small & Mid-Cap Conference on May 21st, and the annual general meeting on June 1st. Fundamentally, during the first nine months of 2025, the company had targeted a 2025 revenue between €155 and €170 million, dependent on the delivery schedule of the chikungunya vaccine active substance to low and middle-income countries. The company also cited the suspension of the IXCHIQ license in the United States by the FDA as a risk, impacting the travelers' segment.

The Stock Breaks Below the Lower Bollinger Band

At €2.196, Valneva is trading below the lower boundary of the Bollinger Bands set at €2.22, a configuration that indicates an acceleration of selling pressure beyond the usual standard deviation. The RSI has fallen to 27, in a pronounced oversold territory. The price is also well below the 50-day moving average (€3.52) and the 200-day moving average (€3.88), confirming a medium-term bearish trend. Over three months, the stock has lost 47.36%. The break of the support at €2.32 has pushed the price towards the residual threshold of €2.26, opening a technical space without recent graphical reference.